Cell Impact AB AI Stock Analysis
Want to see SE:CI full AI Analyst Report?
Cell Impact AB (CI) AI Stock Analysis
Cell Impact AB
(Nasdaq OMX AB:CI)
The overall score is extremely low, reflecting a company in severe financial distress. The most significant factor is the fundamentally unprofitable business model, evidenced by negative gross margins and massive cash burn that is rapidly consuming the company's remaining equity. This is compounded by a deeply bearish technical trend and a negative P/E ratio, indicating no earnings power. The only minor mitigating factor is a clean balance sheet with low debt, but this is insufficient to offset the overwhelming operational and market risks.
Cell Impact AB (CI) vs. iShares MSCI Sweden ETF (EWD)
- Market Cap
- SEK 4.40M
- Dividend Yield
- ―
- Average Volume (3M)
- 11.42M
- Price to Earnings (P/E)
- -0.1
- Beta (1Y)
- 0.91
- Revenue Growth
- -15.92%
- EPS Growth
- 62.91%
- Country
- Sweden
- Employees
- 26
- Sector
- General
- Sector Strength
- 55
- Industry
- Manufacturing - Metal Fabrication
Cell Impact AB Business Overview & Revenue Model
Company Description
Cell Impact AB (publ) is a Swedish firm that specializes in the global production and distribution of bipolar flow plates, which are crucial components for hydrogen fuel cells. The company's products include plates designed with meticulously precise...
Cell Impact AB Financial Statement Overview
Summary
Financial performance is critically weak. The income statement shows a revenue collapse and deeply negative gross margins, leading to massive net losses. The cash flow statement confirms an unsustainable cash burn rate that threatens the company's viability. The balance sheet is the only relative strength, with very low debt, but equity is being rapidly eroded. Overall, the core business is fundamentally unprofitable and faces existential risk.
Income Statement
8Very NegativeBalance Sheet
55NeutralCash Flow
5Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 5.63M | 5.57M | 37.33M | 47.26M | 76.81M | 71.35M |
| Gross Profit | -148.82M | -121.42M | 5.42M | 25.45M | 36.94M | 34.88M |
| EBITDA | -43.91M | -55.03M | -71.45M | -97.72M | -86.22M | -67.85M |
| Net Income | -113.19M | -131.98M | -100.43M | -121.40M | -104.22M | -79.85M |
Balance Sheet | ||||||
| Total Assets | 141.13M | 163.37M | 261.25M | 381.93M | 401.51M | 238.72M |
| Cash, Cash Equivalents and Short-Term Investments | 11.23M | 10.86M | 20.39M | 99.89M | 164.67M | 28.56M |
| Total Debt | 8.48M | 32.54M | 30.92M | 42.75M | 44.70M | 19.51M |
| Total Liabilities | 19.51M | 42.34M | 42.16M | 78.56M | 77.17M | 96.10M |
| Stockholders Equity | 121.63M | 121.03M | 219.08M | 303.37M | 324.35M | 142.63M |
Cash Flow | ||||||
| Free Cash Flow | -31.74M | -47.29M | -76.66M | -152.75M | -174.32M | -140.39M |
| Operating Cash Flow | -31.02M | -45.36M | -62.23M | -100.97M | -105.93M | -86.08M |
| Investing Cash Flow | -712.00K | 2.30M | -14.43M | -51.78M | -68.40M | -54.32M |
| Financing Cash Flow | 36.31M | 33.68M | -2.84M | 88.09M | 310.47M | 17.01M |
Cell Impact AB Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:CI, the sentiment is Neutral. The current price of 0.01 is below the 20-day moving average (MA) of 0.02, below the 50-day MA of 0.03, and below the 200-day MA of 0.08, indicating a neutral trend. The MACD of -0.00 indicates Negative momentum. The RSI at 49.51 is Neutral, neither overbought nor oversold. The STOCH value of 23.81 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SE:CI.
Cell Impact AB Peers Comparison
Overall Rating
SE:OSSD45Neutral
SE:ANNX44Neutral
SE:FLUO43Neutral
SE:SCIB40Underperform
SE:CLBIO39Underperform
SE:CI38Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| 45Neutral | SEK 387.19M | -7.74 | ― | ― | -11.89% | -11.85% | |
| 44Neutral | SEK 78.81M | -2.05 | ― | ― | ― | 7.33% | |
| 43Neutral | SEK 479.03M | -6.58 | ― | ― | ― | -23.57% | |
| 40Underperform | SEK 135.27M | -0.71 | -415.20% | ― | 54.94% | 47.64% | |
| 39Underperform | SEK 371.09M | -28.83 | ― | ― | 54.37% | 52.22% | |
| 38Underperform | SEK 19.90M | -0.05 | ― | ― | -15.92% | 62.91% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| SE:CI | Cell Impact AB | 0.01 | -0.30 | -95.82% | |
| SE:SCIB | SciBase Holding AB | 9.10 | -11.82 | -56.50% | |
| SE:ANNX | Annexin Pharmaceuticals AB | 9.00 | -15.82 | -63.74% | |
| SE:OSSD | OssDsign AB | 3.49 | -7.47 | -68.16% | |
| SE:CLBIO | Corline Biomedical AB | 14.40 | -3.55 | -19.78% | |
| SE:FLUO | FluoGuide A/S | 29.80 | -9.40 | -23.98% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 13, 2026
